Hypertension and sympathetic nervous system: Influence of heart rate on prognosis;Bluthochdruck und sympathisches nervensystem: Einfluss der herzfrequenz auf die prognose

Herz Kreislauf

Volumn 31, Issue 6, 1999, Pages 247-253

  Scholze, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Blood Pressure; Cardiovascular risk; Essential hypertension; Heart rate; Sympathetic nervous system; Therapy

Indexed keywords

ADRENERGIC SYSTEM; CORONARY RISK; ESSENTIAL HYPERTENSION; HEART RATE; HUMAN; PATHOGENESIS; REVIEW;

EID: 0033027939     PISSN: 00467324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Brück H, Schäfers RF, Daul AE, Philipp Th, Wenzel RR. Methoden zur Erfassung der Sympathikusaktivität. Fortschi Med 1998' 116' 41-2.
2. Collins R, Peto R, MacMahon S. Blood pressure, stioke and coronary heart disease. Lancet 1990; 335: 827-38
3. Dominiak P. Sieralowski L, Brasch H. Wechselwirkungen zwischen Angiotensin II und dem sympathischen Nervensystem. In: Philipp I Schäfers RF. Hrsg. Angiotensin //-Antagonismus. Berlin-Heidelberg-New York: Springer Verlag 1996: 56-66.
4. Dominiak P. Antisympathotonika. In: Scholze J, Hrsg. Hypertonie, Risiken und Begleiterkrankungen - Individualtherapie praxisnah. Berlin. B/ackwell Wissenschaftsverlag 1997: l13.
5. Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction [The Danish Verapamil Infarction Trial II (DAVITII)]. AmJ Card/ol 1990; 66: 779-85.
6. Dyer AR, Stamler J, Shekelle RB, Schoenberger JA, Stamler R, Shekelle S, Berkson DM, Paul 0, Lepper MH, Lindberg HA. Pulse pressure-1. Level and associated factors in four Chicago epidemiologic studies. J Chron Dis 1982, 35:259-73.
7. Dyer AR, Persky V, Stamler J, Paul 0, Shekelle RB, Berkson DM, Lepper M, Schoenberger JA, Lindberg HA. Heart rate as a prognostic factor for coronary diseases and mortality: findings in three Chicago ep/demio/ogic studies. Am J Epidemiol 1980; 112: 736-49.
8. Farinaro E. Italien Tensiopulse Study. Am J Hypertens 1995; 8: 47a.
9. Fischer Hansen J, Hagerup L, Sigurd B, Pedersen F, Mellemgard K, Pedersen-Bjergaard 0, Mortensen LS, for the Danish Verapamil Infarction Trial [DAVIT) Study Group. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapnl versus trandolapril alone. Am J Cardiol 1997; 79: 738-41
10. Furberg C, Psaty BM, Meyer JV. Nifedipine. Doserelated increase in mortality in patients with coronary heart disease. Circulation 1995, 92: 1326-31.
11. Gillum R, Makuo D, Feldman J. Pulse rate, coronary heart disease, and death: the NHANES I epidemiologic study. Am Heart J 1991; 121: 172-7.
12. Gillman MW, Kännel WB, Belanger A, DAgostino RB. Influence of heart rate on mortality among persons with hypertension: The Frammgham Study. Am Heart J 1993; 125: 1148-54.
13. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S and the Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction m ejection fraction. Circulation 199!; 83: 52-60
14. Grossmann E, Messerli FH. Effect of calcium antagonists on plasma norepinephnne levels, heart rate and blood pressure. Am J Cardiol 1997; 80. 1453-8.
15. Habib G. Reappraisal of the importance of heart /ate as a risk factor for cardiovascular morbidity and mortality. Clin Therap 1997, 19 (Suppl. A): 39-52.
16. Hansson L, Zanchetti A, Carruthers G, Dahlöf B, Elmfeldt D, Julius S, Menard J, Rann KH, Wedel H, Westerling S, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351: 1755-62.
17. Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit: a randomized, double-blind, placebo-controlled comparison of recurrent ischaemia in patients treated with nifedipine or metopro/ol or both. Br Heart J 1986; 56:400-13.
18. Israeli SPRINT Study Group. Secondary prevention remfarction Israeli nifedipine trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988:9:354-64.
19. Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K. The association of borderline hypertension with target organ changes and higher coronary risk. Tecumseh Blood Pressure Study. JAMA 1990; 264:354-8.
20. Julius S. Sympathetic hyperactiv/ty and coronary risk in hypertension. Hypertension 1993; 21: 886-93.
21. Julius S, Jamerson K. Sympathetics, insulin resistance and coronary risk in hypertension: the chicken and egg question. J Hypertens 1994; 12: 495-502.
22. Julius S. Evolution of Hemodynamic and Neuroendocrine Changes in the Course of Hypertension. In: Messerli FH, ed. The ABC s of Ant/hypertensive Therapy. New York: Raven Press 1994: 17.
23. Lund-Johansen P, Omvik P. Hemodynamic patterns of untreated hypertensive disease. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophys/ology, diagnosis and management. New York: Raven Press 1990:305-27.
24. Messerli FH. Rational Antihypertensive Therapy: Overview. In: Messerli FH, ed. The ABC s of Antihypertensive Therapy. New York: Raven Press 1994: 131.
25. Middeke M. Chronopathology of blood pressure in the early stage of hypertension. In: Lemmer B, ed. From the biological dock to chronopharmaco/ogy. Stuttgart' Medpharm Scientific PubJ. 1996: 119-28.
26. Mold G, von Bielinski C, Middeke M, Lemmer B. Age-dependent changes in blood pressure and heart rate in essential hypertension. Chronob/ol Int 1996: 13 (Suppl. 1): 98.
27. Osol G. Mechanotransduction by vascular smooth muscle. J Vase Res 1995:32:275-92.
28. Palatini P, Julius S. Heart rale and the ca/d/ovascu/arrisk. jHypertens 1997: 15:3-17
29. Rehnquist N, Hjemdahl P, Billing E, Björkander I, Eriksson SV, Forslund L, Held C, Nasman P, Wallen N H. Effects of metopro/ol i/s verapamil in patients with stable angina pector/s. Eur Heart J 1996: 17: 76-81.
30. Scholze J. Einf/uss der Hämodynamik auf die D/ffe-rentialtherapie. In: Scho/ze J, Hrsg. Hypertonie, Risiken und Begleiterkrankungen - Individualtherapie praxisnah. Berlin.' B/ackwe/l Wissenschafts-Ver/ag 1997: 166.
31. Schrader J, Schoel G, Scheler E. Bedeutung der 24-Stunden-Blutdruckmessung in der Diagnostik und Therapie der arteriellen Hypertonie. Klin Wochenschr 1990: 68: 1119-26.
32. Stamler J, Berkson DM, Dyer A, Lepper MH, Lindberg HA, Paul 0, et al.. Relationship of multiple variables to blood pressure - findings from four Chicago epidemiologic studies. In. Miami PO, ed. Epidemiology and Control of Hypertension. Symposia Specialists 1975. 307-52